Breast Cancer Clinical Trials Near You

The breast cancer clinical trial landscape in 2026 is dominated by antibody-drug conjugates (ADCs), which deliver chemotherapy directly to cancer cells while sparing healthy tissue. Trastuzumab deruxtecan (Enhertu) has reshaped treatment for HER2-low tumors — a category that didn't exist five years ago — and new ADCs targeting Trop-2 and HER3 are in Phase 2–3 testing.

For triple-negative breast cancer (TNBC), combination immunotherapy with PD-1/PD-L1 checkpoint inhibitors is being tested alongside novel targets like TIGIT and LAG-3, aiming to improve the historically limited treatment options for this aggressive subtype.

CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) remain the backbone of HR-positive treatment. Trials are now exploring whether adding them to neoadjuvant therapy before surgery can shrink tumors more effectively. De-escalation studies ask whether some early-stage patients can safely skip chemotherapy entirely based on genomic profiling tools like Oncotype DX and MammaPrint.

PARP inhibitors, originally approved for BRCA-mutated cancers, are being tested in broader populations and in combination with immunotherapy. Cell therapy approaches, including tumor-infiltrating lymphocyte (TIL) therapy and bispecific antibodies, are also entering breast cancer trials.

Patient considerations: Many breast cancer trials now require tissue samples for biomarker testing (HER2, HR status, genomic assays). Trials increasingly accept patients who have already received standard treatment, so prior therapy often helps rather than hinders eligibility. Ask your oncologist about comprehensive genomic profiling early — your tumor's molecular profile determines which cutting-edge trials you may qualify for.